Conflicts of Interest: More Questions than Answers
Executive Summary
It was fitting that this year's TCT conference included a session on physician/industry conflicts of interest since this has been a hot topic recently in the press, and because TCT is probably the most industry-focused of all the major clinical conferences. Not surprisingly, the panel of physicians raised more questions than answers about both individual and institutional conflicts and how they should be handled.
You may also be interested in...
In the Eye of the Storm
Over the past several years, increased public scrutiny, from both Federal agencies and the general media, have focused on the close collaborations between product companies and the physicians who help them develop and test new products, alleging that some relationships are too close leading to physicians who put personal financial gain ahead of patient care. Though it was recently cleared by the Department of Justice in a high profile whistle blower case, few companies have found themselves as closely watched as spine leader Medtronic Sofamor Danek.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.